Back to search
FDAFDA · Food and drugs·Recall number Z-0875-2017

NeuViz 64 Multi-slice CT Scanner Systems

Published January 4, 2017 · Recall initiated: August 31, 2016

Summary

FDA records medical device Class II recall Z-0875-2017, published January 4, 2017 and initiated August 31, 2016. Recalling firm: Neusoft Medical Systems Co., Ltd.; Status: Terminated; Reported quantity: 23 units; Lot: NeuViz 64e, NeuViz 64i with software version 1.0.6.3258 +P04 or previous version. NeuViz 64En, NeuViz 641n with software version 1.0.7.4021+P05 or previous version. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

The Firm discovered during contrast agent tracking scan, when the expected concentration of contrast agent is reached, later planned scan may be interrupted. The system must be powered down and restarted to clear the interruption error before scanning can resume.

What to do

FDA Mandated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Neusoft Medical Systems Co., Ltd.
Distributor
US Distribution
Lot
NeuViz 64e, NeuViz 64i with software version 1.0.6.3258 +P04 or previous version. NeuViz 64En, NeuViz 641n with software version 1.0.7.4021+P05 or previous version
Risk classification
Class II
Area (FDA)
device
Country
China

Related recalls

Questions about this recall

Was NeuViz 64 Multi-slice CT Scanner Systems recalled?

Yes. FDA published recall Z-0875-2017 on January 4, 2017. Reported hazard: The Firm discovered during contrast agent tracking scan, when the expected concentration of contrast agent is reached, later planned scan may be interrupted. The system must be powered down and restarted to clear the interruption error before scanning can resume.

What should I do if I have this product?

FDA Mandated · Letter